Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina develops DNA sequencing, array-based, informatics and proteomics technologies for research, clinical and applied markets. Company news commonly covers sequencing instruments and consumables, NovaSeq X demand, DRAGEN software releases, TruPath Genome analytical support, and applications in oncology, reproductive health, agriculture, rare disease and drug discovery.
Illumina updates also include collaborations around precision oncology testing, preventive and population genomics, pediatric cancer and rare disease data, and the Alliance for Genomic Discovery. Financial and corporate news covers revenue trends, operating margins, earnings guidance, share repurchase authorizations, acquisitions in multiomics and proteomics, and board or management changes.
Illumina is supporting a project that combines genomics with citizen science to monitor ocean health in the South-West Pacific region. The Citizens of The Sea project, led by Xavier Pochon from the Cawthron Institute, equips seafaring vessels with environmental DNA (eDNA) sample collection kits. These samples are then analyzed by Sequench laboratory in New Zealand, creating powerful datasets to understand and improve ocean health.
This initiative demonstrates Illumina's commitment to environmental stewardship and sustainable future. The project leverages Illumina's expertise in genomic sequencing to contribute to marine conservation efforts, showcasing the company's involvement in innovative environmental monitoring techniques.
Illumina (NASDAQ: ILMN) has won a significant legal victory as the European Court of Justice (ECJ) ruled that the European Commission lacked jurisdiction over Illumina's acquisition of GRAIL. This decision removes the basis for a 432 million euro fine previously imposed on Illumina. The ruling comes after Illumina's spin-off of GRAIL in June 2024, which resulted in GRAIL becoming an independent public company. Illumina now holds a 14.5% minority stake in GRAIL and will continue to support it with sequencing technology and services. Additionally, in the United States, the FTC Commissioners dismissed the case against Illumina and GRAIL on August 15, 2024, following the successful spin-off, concluding the US proceedings.
GRAIL, Inc. (Nasdaq: GRAL) has published findings on the performance of its Galleri® multi-cancer early detection (MCED) test for prostate cancer in JCO Precision Oncology. The data, from the CCGA and PATHFINDER studies, show that Galleri preferentially detects aggressive, clinically significant prostate cancers over slow-growing cases.
Key findings include:
- 93% of detected prostate cancers were intermediate or high grade
- 67% were stage III or IV
- Cancer signal of origin prediction accuracy was >90%
- No low-grade cancers were detected
- Only 4.2% of stage I and II cancers were detected
These results suggest that Galleri could be valuable in population-based screening programs without contributing to overdiagnosis of indolent prostate cancers.
Illumina (NASDAQ: ILMN) has received FDA approval for its TruSight Oncology (TSO) Comprehensive test, a 500+ gene biomarker test for solid tumors. This in vitro diagnostic (IVD) kit is the first FDA-approved, distributable comprehensive genomic profiling test with pan-cancer companion diagnostic claims. It includes two companion diagnostic (CDx) indications:
1. Identifying patients with NTRK gene fusions for treatment with Bayer's VITRAKVI (larotrectinib)
2. Detecting RET fusion-positive non-small-cell lung cancer (NSCLC) patients for treatment with Lilly's RETEVMO (selpercatinib)
The test aims to improve access to localized precision oncology and increase the chances of finding actionable biomarkers. TSO Comprehensive will begin shipping to customers this year and is reimbursable under CMS national coverage determination.
Illumina (NASDAQ: ILMN) has announced a new strategy to accelerate value creation, aiming to boost revenue growth to high single digits over the next three years. The company plans to achieve this through innovations in its core genomics portfolio, enabling transformative applications using multiomics and offering higher quality insights to customers. Illumina expects to deliver double-digit to teens non-GAAP diluted earnings per share growth from 2025-2027.
The company is also partnering with the Broad Institute of MIT and Harvard to advance single-cell sequencing, leveraging Illumina's Fluent technology. Key focus areas include reinventing the genome, unlocking deeper biology, simplifying NGS operations, and turning data into insights. Illumina aims to accelerate revenue growth while improving profitability through operational efficiencies and strategic cash flow allocation.
Illumina announced its Q2 2024 financial results, reporting core revenue of $1.09 billion, a 6% decrease year-over-year but a 3% increase from Q1 2024. GAAP operating margin was 40.5% and non-GAAP operating margin was 22.2%. GAAP diluted EPS stood at $0.41 while non-GAAP diluted EPS was $1.09. The company has adjusted its 2024 revenue guidance to a decline of 2% to 3% from 2023, but raised non-GAAP operating margin guidance to 20.5% to 21% and introduced non-GAAP diluted EPS guidance of $3.80 to $3.95.
The spin-off of GRAIL was completed on June 24, 2024. Consolidated results include a $1,466 million goodwill impairment and $420 million intangible asset impairment related to GRAIL. Consolidated revenue was $1.112 billion, with an operating loss of $1,637 million, and net loss of $1,988 million. Cash flow from operations was $80 million, with a free cash flow of $48 million.
Illumina Inc. (NASDAQ: ILMN) has expanded its oncology menu for NovaSeq™ X Series customers, launching high-throughput versions of TruSight™ Oncology 500 (TSO 500 HT) and TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2). These assays enable labs to expand oncology testing research with improved sequencing economics, faster run times, and larger batch sizes.
The TSO 500 HT on NovaSeq X Series offers increased throughput and economic improvements compared to the NovaSeq 6000 System. TSO 500 ctDNA v2 provides a faster, more sensitive liquid biopsy CGP workflow from blood samples. Key improvements include 40% faster sequencing run times, a three-day total assay turnaround time, and ambient temperature shipping for consumables.
Illumina, a global leader in genomics, is showcasing how its employees contribute to world-changing impacts through their work in DNA sequencing and array-based life sciences technologies. The company has released a video series highlighting employee experiences in the field of genomics at Illumina. Illumina's vision includes making genome sequencing more accessible, advancing personalized medicine, and improving outcomes for those facing diseases.
Illumina's products are driving innovations in various fields, including oncology, genetic and infectious diseases, and reproductive health. The company's technology is enabling continuous innovation towards solutions that positively impact both people and the planet. Illumina is inviting interested individuals to learn more about career opportunities and the company's impact in the genomics sector.
Illumina (NASDAQ: ILMN) has announced a Strategy Update presentation scheduled for August 13, 2024, starting at 8:00am Pacific Time. This event will feature presentations from Illumina's executive team, followed by a Q&A session.
Interested participants can access the webcast through the Events & Presentations section of Illumina's Investor Relations website. Pre-registration is recommended and can be done on the company's website or via a provided registration link. A replay of the event will be available on the Investor Relations website for at least 30 days after the presentation.
This update comes following a previous announcement on June 24, highlighting Illumina's commitment to keeping investors and stakeholders informed about the company's future plans and strategies.
Illumina Ventures, a leading genomics and precision health venture firm, has announced the addition of two new advisors: Dr. Timothy Stenzel and Jerry Steiner. Dr. Stenzel, former director of the FDA's Office of In Vitro Diagnostics, brings extensive experience in molecular diagnostics and regulatory affairs. Jerry Steiner, former executive VP of Sustainability at Monsanto, offers deep insights into agricultural biotech and sustainability.
These appointments strengthen Illumina Ventures' expertise in navigating complex regulatory environments and identifying opportunities in sustainable agriculture through genomics. The firm aims to support innovative diagnostics companies and apply genomics to address global climate change challenges.